Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
590M
-
Number of holders
-
1203
-
Total 13F shares, excl. options
-
502M
-
Shares change
-
+25.5M
-
Total reported value, excl. options
-
$37.1B
-
Value change
-
+$1.96B
-
Put/Call ratio
-
0.46
-
Number of buys
-
448
-
Number of sells
-
-627
-
Price
-
$74.03
Significant Holders of Edwards Lifesciences Corp - Common Stock (EW) as of Q4 2024
1,412 filings reported holding EW - Edwards Lifesciences Corp - Common Stock as of Q4 2024.
Edwards Lifesciences Corp - Common Stock (EW) has 1,203 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 502M shares
of 590M outstanding shares and own 84.99% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (69.1M shares), BlackRock, Inc. (54.5M shares), WELLINGTON MANAGEMENT GROUP LLP (33.2M shares), STATE STREET CORP (25.8M shares), Bank of New York Mellon Corp (18.1M shares), JPMORGAN CHASE & CO (14.9M shares), GEODE CAPITAL MANAGEMENT, LLC (13.6M shares), Fisher Asset Management, LLC (9.78M shares), CITADEL ADVISORS LLC (9.42M shares), and NORGES BANK (8.25M shares).
This table shows the top 1203 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.